{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:39:51Z","timestamp":1791164391088,"version":"4.1.0"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,12,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>More efficacious, less toxic combinations are needed to treat platinum-sensitive recurrent epithelial ovarian cancer (EOC). Pemetrexed is a multitargeted antifolate with manageable toxicity and has been combined with carboplatin to treat other cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>This is a phase II study of carboplatin area under the curve 5 with pemetrexed 500 mg\/m<jats:sup>2<\/jats:sup>administered intravenously on day 1 every 21 days for six cycles or for up to eight cycles if clinical benefit occurred. Eligible patients had platinum-sensitive recurrent EOC, peritoneal serous cancer, or fallopian tube cancer. The primary objective was to determine response rate defined by Response Evaluation Criteria in Solid Tumors; other end points included toxicities, progression-free survival (PFS), and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-five patients were accrued; 44 patients received treatment. Overall response rate was 51.1%; there were no complete responses (0%), 23 confirmed partial responses (51.1%), two unconfirmed partial responses (4.4%), 14 patients with stable disease (31.1%), and two patients with progressive disease after two cycles (4.4%). Grade 3 and 4 hematologic toxicities included neutropenia (41%), thrombocytopenia (23%), and anemia (9%); there were no episodes of febrile neutropenia. Grade 3 and 4 nonhematologic toxicities included fatigue (11%), nausea (5%), vomiting (5%), diarrhea (5%), syncope (5%), and pulmonary embolism (5%). Median PFS time was 7.57 months (95% CI, 6.44 to 10.18 months), mean OS time was 20.3 months, and median OS has not yet been reached with a mean follow-up time of 15.3 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Carboplatin\/pemetrexed is a well-tolerated regimen with activity in platinum-sensitive recurrent EOC; further testing of this regimen in platinum-sensitive EOC patients is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.17.0282","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T02:37:27Z","timestamp":1226371047000},"page":"5761-5766","source":"Crossref","is-referenced-by-count":35,"title":["Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer"],"prefix":"10.1200","volume":"26","author":[{"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn N.","family":"Krasner","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Berlin","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Roche","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pereira","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kendall","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Gynecologic Oncology, Brigham and Women's Hospital; and Biostatistics Center and Department of Hematology and Oncology, Massachusetts General Hospital, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.389"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0913"},{"key":"R5","unstructured":"Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo(2,3-d)pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116,1997-1123,"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Westerhof GR, Schornagel JH, Kathmann I, et al: Carrier and receptor mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular structure and biological activity. Mol Pharmacol 48:459,1995-471,","DOI":"10.1016\/S0026-895X(25)10494-X"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-040010"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37476"},{"key":"R9","unstructured":"Wu M, Gunning W, Ratnam M: Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8:775,1999-782,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9722-5"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.073"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.7016"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21480"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.06.028"},{"key":"R18","unstructured":"Castells MC, Tennant NM, Sloane DE, et al: Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol [epub ahead of print on May 23, 2008]"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.17.0282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T16:54:54Z","timestamp":1738515294000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.17.0282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,10]]},"references-count":17,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2008,12,10]]}},"alternative-id":["10.1200\/JCO.2008.17.0282"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.17.0282","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,10]]}}}